This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


trusted source


New molecular insights into medical cannabis

New molecular insights into medical cannabis
End-point assays of compounds tested. (A) Chemical representation of Δ9-trans-tetrahydrocannabinol (THC), cannabidiol-dimethylheptyl (CBD-DMH), 9(R)-Δ6a,10a-THC (6a10aTHC), JWH018, tetrahydrocannabinolic acid, 2-arachidonoylglycerol, cannabidiol (CBD), and anandamide. (B, C) End-point assay for (B) ATX-β and (C) ATX-ɣ inhibition with various cannabinoids and endocannabinoids. All error bars represent the SEM (n = 3). (B, C) Activity rate of 99 and 65 mMol end product/mM ATX/min has been found for (B, C), respectively. ANOVA comparison between CTRL and other conditions showed statistically significant differences for THC, 6a10aTHC, tetrahydrocannabinolic acid, CBD, and 5-DMH-CBD for ATX-β and ATX-γ inhibition (P < 0.005). ATX was not significantly inhibited by JWH018, anandamide, and 2-arachidonoylglycerol (P > 0.005). Credit: Life Science Alliance (2023). DOI: 10.26508/lsa.202201595

In various European countries and North America, medical cannabis or medicines based on cannabinoids are authorized for therapeutic purposes. While the cannabis plant contains over 100 cannabinoids, THC (D9-tetrahydrocannabinol) and CBD (cannabidiol) are the two best known and characterized constituents.

THC and CBD are administered under different pharmaceutical forms, showing therapeutic effects such as pain and inflammation relief. However, little is known about how THC and other cannabinoids work in the at the molecular level.

Based on , -containing medications can help to alleviate symptoms of mental disorders such as epilepsy, Alzheimer's disease, asthma, and cancer, and help prevent weight loss during clinically challenging treatments for AIDS and different forms of cancer.

EMBL Grenoble researchers have investigated the interaction between THC and some proteins it might bind to. In a recent study, they showed in vitro that THC inhibits an important human called autotaxin. This enzyme is involved in many different cellular functions, specifically producing a molecule called lysophosphatidic acid (LPA), which stimulates cell proliferation. A dysregulation of LPA production can lead to development of cancer, inflammation, or pulmonary fibrosis. Autotaxin is therefore a major target for drug development.

New molecular insights on THC

Understanding how THC and other cannabinoids interact in our cells at the would help to administer THC more efficiently in therapeutic contexts.

The field of structural biology is particularly relevant to obtain this kind of information. Structural biologists focus on elucidating at the atomic scale the three-dimensional structure of molecules, like proteins or enzymes, and how they interact with each other. These structural results further lead to understanding molecules' particular function and how to modulate their activities with specific compounds—which are crucial insights to develop effective drugs.

The first step in structural and biochemical studies is to determine how a specific component interacts with molecules in vitro—meaning in the controlled environment of the laboratory—before going for further investigation in vivo, in living organisms.

During their investigation of THC, the McCarthy team obtained the three-dimensional structure of the THC cannabinoid bound with autotaxin. By employing macromolecular crystallography with EMBL's beamline at the PETRA III synchrotron in Hamburg, they could lay the molecular basis of how THC inhibits this enzyme.

A path to further investigations

Identifying this enzyme as a binding target for THC expands the knowledge on this cannabinoid and provides more data on its possible therapeutic effects at the and how might contribute to therapy.

"Autotaxin is an essential enzyme in human beings," said Mathias Eymery, Ph.D. student on the McCarthy team and first author of the publication. "It is responsible for the production of LPA, a major membrane-derived lipid signaling molecule that mediates many different cellular functions. Dysregulations of LPA production by autotaxin are known to have a role in the development of cancer, inflammation, or pulmonary fibrosis."

In vivo studies are necessary to confirm that the binding between autotaxin and THC is linked to the of THC administration—as the main known targets of THC in the human body are the CB1 and CB2 cannabinoid receptors, that mediate the psychoactive and pain relieve effects of cannabinoids. Further investigation will help determine further potential of cannabinoids for medical research and drug development.

The work is published in the journal Life Science Alliance.

More information: Mathias C Eymery et al, Linking medicinal cannabis to autotaxin–lysophosphatidic acid signaling, Life Science Alliance (2023). DOI: 10.26508/lsa.202201595

Citation: New molecular insights into medical cannabis (2023, January 9) retrieved 22 June 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Study shows cannabis terpenes provide pain relief, contribute to 'entourage effect'


Feedback to editors